Summary of scheduled assessment and follow-up during the study
| Evaluations | Visit 0 | Visit 1–8 | Visit 9 | Visit 10 | Visit 11 | Visit 12 | Visit 13 |
| Discharge | Month: 0–6 after discharge | Month: 12 after discharge | Month: 18 after discharge | Month: 24 after discharge | Month: 30 after discharge | Month: 36 after discharge | |
| Informed consent | X | ||||||
| Inclusion/exclusion criteria | X | ||||||
| Randomisation | X | ||||||
| Demographic data | X | ||||||
| Clinical data | X | ||||||
| Blood sample | X | X | |||||
| BMI | X | X | X | ||||
| Sarcopenia | X | X | X | ||||
| Haematological indicators | X | X | X | ||||
| QoL (EORTC QLQ-C30) | X | X | X | ||||
| ω-3 PUFAs intakes in diet | X | X | |||||
| Chemotherapy tolerance | X | ||||||
| Chemotherapy toxicity | X | ||||||
| Adherence to interventions | X | ||||||
| Adverse events | X | ||||||
| Unplanned readmission | X | ||||||
| CT or MRI | X | X | X | X | X | X | |
| Tumour markers | X | X | X | X | X | X | |
| Endoscopy | X | X | X | ||||
| DFS | X | ||||||
| OS | X |
BMI, body mass index; DFS, disease-free survival; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer core quality of life questionnaire; OS, overall survival; QoL, quality of life.